Patients in Egypt can now benefit from a new first-in-class overactive bladder treatment
- More than 500 million people around the world are affected by OAB
- Around 40% of the OAB patients are silent sufferers and have never consulted a physician about their condition
- Urinary dysfunction should not be considered as natural part of ageing
- Astellas Pharma – World category leader in Urology- launches BETMIGA in Egypt
Cairo, Egypt; November 24, 2016: Egyptian patients suffering from overactive bladder (OAB) can now benefit from a new innovative treatment launched by Astellas Pharma. Mirabegron is the first therapy in its class that has been approved in over 30 years. Currently around half of the patients discontinue OAB treatment after only three months, often due to lack of efficacy or side effects. Studies have shown that Mirabegron has low treatment-associated side effects, including dry mouth.
OAB is a group of symptoms that affects more than 500 million people worldwide.1 The condition affects men and women of any age, although it is more common among the elderly.2 The condition can have a profound effect on an individuals’ quality of life, resulting in withdrawal from social and family life, professional environment, physical activities, including spiritual life. In some cases, symptoms can also affect mental and physical wellbeing; study results indicate higher depression and lower quality of life scores.2
“The symptoms are easy to recognise – a sudden forceful urge to urinate, without the ability to delay it, frequent urination (more than eight times in 24 hours)2, or urine leakage. Such symptoms are related to urinary dysfunction, and regardless of the common perception it should not be considered a natural part of aging.” Prof. Hassan Aboeleinin, Professor of Urology, Mansoura University commented on the symptoms and perception of the condition. He continued: “There are a lot of silent sufferers, who due to lack of awareness, social stigma and embarrassment have never consulted a doctor for a correct diagnosis. As many as 40% of people are suffering without medical attention2, despite reliable and efficient treatment options being available to manage the symptoms and improve patients’ quality of life.”
Mirabegron works by stimulating the beta-3 receptors in the muscle of the bladder causing it to relax. As a result, it improves bladders’ storage capacity without inhibiting contractions, thereby prolonging the time between trips to the toilet for the patient.
“Due to uncomfortable side effects, most commonly dry mouth and constipation of the current standard of Care (Antimuscarinics), majority of patients do not take the full course of medications,4 which prevents them from experiencing the benefit of the treatment. With the new option for OAB treatment becoming available, doctors and patients have the opportunity to choose the correct therapy that suits patient’s lifestyle and tolerances. Any treatment should be combined with healthy dietary and lifestyle changes,” added Prof. Sherif Mourad, Professor of Urology, Ain Shams University.
Mr. Ayman Eldeeb, Country Manager Astellas Egypt concluded:
“At Astellas Pharma, we heavily invest in research and development and work to develop pioneering treatments that will improve patients lives. The introduction of Mirabegron should lead to a shift in how OAB is treated in adults, allowing physicians to choose the best option for long-term disease management. We hope increased awareness will change the perception of the condition and silent sufferers will seek medical advice.”
 Irwin D.E., et al. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int 2011; 108(7):1132-8
 Milsom I. et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87(9): 760-766.
 Benner J.S., Nichol M.B., Rovner E.S., et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int 2010; 105(9): 1276–82
 Tyagi P et al. Mirabegron: safety review Expert Opin. Drug Safety 2011;10.2: 287-294.
 Betimga Summary of Product Characteristics. May 2016